
Syncromunerevenue
Fort Lauderdale, FloridaFounded 2020
Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, a potentially first-in-class platform immunotherapy designed to treat metastatic solid tumor cancers.
Syncromune revenue
Syncromune has not published its revenue. Growjo puts it at about $5.9M a year (September 2025).
$0
$2M
$4M
$0
–
$5.9M
20202021–242025
| As of | Revenue | Source |
|---|---|---|
| Sep 2025 | $5.9MEST | Growjo estimate |
Syncromune employees
Syncromune has 34 employees (September 2025, LinkedIn).
0
10
20
30
34
2025
Syncromune FAQ
Categories
Companies in
How this page is sourced
1 from public sources · 1 estimate. Founder figures link to the second they were said; public figures name their source; estimates are marked EST and say whose they are. Not financial advice.
Updated Sep 10, 2026Data disclaimerReport a correctionClaim this profileRun Syncromune? Join the podcast